» Articles » PMID: 33098858

Crystal Structure of a Soluble APOBEC3G Variant Suggests SsDNA to Bind in a Channel That Extends Between the Two Domains

Abstract

APOBEC3G (A3G) is a single-stranded DNA (ssDNA) cytosine deaminase that can restrict HIV-1 infection by mutating the viral genome. A3G consists of a non-catalytic N-terminal domain (NTD) and a catalytic C-terminal domain (CTD) connected by a short linker. While the CTD catalyzes cytosine deamination, the NTD is believed to provide additional affinity for ssDNA. Structures of both A3G domains have been solved individually; however, a full-length A3G structure has been challenging. Recently, crystal structures of full-length rhesus macaque A3G variants were solved which suggested dimerization mechanisms and RNA binding surfaces, whereas the dimerization appeared to compromise catalytic activity. We determined the crystal structure of a soluble variant of human A3G (sA3G) at 2.5 Å and from these data generated a model structure of wild-type A3G. This model demonstrated that the NTD was rotated 90° relative to the CTD along the major axis of the molecule, an orientation that forms a positively charged channel connected to the CTD catalytic site, consisting of NTD loop-1 and CTD loop-3. Structure-based mutations, in vitro deamination and DNA binding assays, and HIV-1 restriction assays identify R24, located in the NTD loop-1, as essential to a critical interaction with ssDNA. Furthermore, sA3G was shown to bind a deoxy-cytidine dinucleotide near the catalytic Zn, yet not in the catalytic position, where the interactions between deoxy-cytidines and CTD loop-1 and loop-7 residues were different from those formed with substrate. These new interactions suggest a mechanism explaining why A3G exhibits a 3' to 5' directional preference in processive deamination.

Citing Articles

Molecular mechanism for regulating APOBEC3G DNA editing function by the non-catalytic domain.

Yang H, Pacheco J, Kim K, Bokani A, Ito F, Ebrahimi D Nat Commun. 2024; 15(1):8773.

PMID: 39389938 PMC: 11467180. DOI: 10.1038/s41467-024-52671-1.


Next generation APOBEC3 inhibitors: Optimally designed for potency and nuclease stability.

Hedger A, Myint W, Lee J, Suchenski-Loustaunau D, Balachandran V, Shaqra A bioRxiv. 2024; .

PMID: 39282427 PMC: 11398451. DOI: 10.1101/2024.09.05.611238.


Molecular mechanism for regulating APOBEC3G DNA editing function by the non-catalytic domain.

Yang H, Pacheco J, Kim K, Ebrahimi D, Ito F, Chen X bioRxiv. 2024; .

PMID: 38559028 PMC: 10980023. DOI: 10.1101/2024.03.11.584510.


The structural basis for HIV-1 Vif antagonism of human APOBEC3G.

Li Y, Langley C, Azumaya C, Echeverria I, Chesarino N, Emerman M Nature. 2023; 615(7953):728-733.

PMID: 36754086 PMC: 10033410. DOI: 10.1038/s41586-023-05779-1.


Structural basis for HIV-1 antagonism of host APOBEC3G via Cullin E3 ligase.

Ito F, Alvarez-Cabrera A, Liu S, Yang H, Shiriaeva A, Zhou Z Sci Adv. 2023; 9(1):eade3168.

PMID: 36598981 PMC: 9812381. DOI: 10.1126/sciadv.ade3168.


References
1.
Kouno T, Luengas E, Shigematsu M, Shandilya S, Zhang J, Chen L . Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat Struct Mol Biol. 2015; 22(6):485-91. PMC: 4456288. DOI: 10.1038/nsmb.3033. View

2.
Bishop K, Holmes R, Sheehy A, Davidson N, Cho S, Malim M . Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol. 2004; 14(15):1392-6. DOI: 10.1016/j.cub.2004.06.057. View

3.
Betts L, Xiang S, Short S, Wolfenden R, Carter Jr C . Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J Mol Biol. 1994; 235(2):635-56. DOI: 10.1006/jmbi.1994.1018. View

4.
Bogerd H, Doehle B, Wiegand H, Cullen B . A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A. 2004; 101(11):3770-4. PMC: 374319. DOI: 10.1073/pnas.0307713101. View

5.
Huthoff H, Malim M . Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol. 2007; 81(8):3807-15. PMC: 1866099. DOI: 10.1128/JVI.02795-06. View